Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.

<h4>Background</h4>Venous thromboembolism (VTE) is a multicausal disease which recurs. Hematocrit is associated with a thrombotic risk. We aimed to investigate if hematocrit is associated with the recurrence risk.<h4>Methods</h4>Patients with a first VTE were followed after a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lisbeth Eischer, Verena Tscholl, Georg Heinze, Ludwig Traby, Paul A Kyrle, Sabine Eichinger
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3939f7a1fad14d4291dae1952ed21202
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3939f7a1fad14d4291dae1952ed21202
record_format	dspace
spelling	oai:doaj.org-article:3939f7a1fad14d4291dae1952ed212022021-11-18T07:16:08ZHematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.1932-620310.1371/journal.pone.0038705https://doaj.org/article/3939f7a1fad14d4291dae1952ed212022012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701697/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Venous thromboembolism (VTE) is a multicausal disease which recurs. Hematocrit is associated with a thrombotic risk. We aimed to investigate if hematocrit is associated with the recurrence risk.<h4>Methods</h4>Patients with a first VTE were followed after anticoagulation. Patients with VTE provoked by a transient risk factor, natural inhibitor deficiency, lupus anticoagulant, homozygous or double heterozygous defects, cancer, or long-term antithrombotic treatment were excluded. The study endpoint was recurrent VTE.<h4>Results</h4>150 (23%) of 653 patients had recurrence. Only high hematocrit was significantly associated with recurrence risk [hazard ratio (HR) for 1% hematocrit increase with the third tertile 1.08; 95% CI 1.01-1.15]. No or only a weak association for hematocrits within the first and second tertile was seen (HR 1.03; 95% CI 0.97-1.09, and 1.07; 95% CI 1.00-1.13). Hematocrit was associated with recurrence risk only among women. After five years, the probability of recurrence was 9.9% (95% CI 3.7%-15.7%), 15.6% (95% CI 9.7%-21.2%) and 25.5% (95% CI 15.1%-34.6%) in women, and was 29.2% (95% CI 21.1%-36.5%), 30.1% (95% CI 24.1%-35.7%) and 30.8% (95% CI 22.0%-38.7%) in men for hematocrits in the first, second and third tertile, respectively. Men had a higher recurrence risk (1.9; 95% CI 1.1-2.7; p = 0.03), which dropped by 23.5% after adjustment for hematocrit. Hematocrit was not a significant mediator of the sex-difference in recurrence risk (p = 0.223).<h4>Conclusions</h4>High hematocrit is associated with the recurrence only in women. The different recurrence risk between men and women is possibly partly explained by hematocrit.Lisbeth EischerVerena TschollGeorg HeinzeLudwig TrabyPaul A KyrleSabine EichingerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e38705 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lisbeth Eischer Verena Tscholl Georg Heinze Ludwig Traby Paul A Kyrle Sabine Eichinger Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
description	<h4>Background</h4>Venous thromboembolism (VTE) is a multicausal disease which recurs. Hematocrit is associated with a thrombotic risk. We aimed to investigate if hematocrit is associated with the recurrence risk.<h4>Methods</h4>Patients with a first VTE were followed after anticoagulation. Patients with VTE provoked by a transient risk factor, natural inhibitor deficiency, lupus anticoagulant, homozygous or double heterozygous defects, cancer, or long-term antithrombotic treatment were excluded. The study endpoint was recurrent VTE.<h4>Results</h4>150 (23%) of 653 patients had recurrence. Only high hematocrit was significantly associated with recurrence risk [hazard ratio (HR) for 1% hematocrit increase with the third tertile 1.08; 95% CI 1.01-1.15]. No or only a weak association for hematocrits within the first and second tertile was seen (HR 1.03; 95% CI 0.97-1.09, and 1.07; 95% CI 1.00-1.13). Hematocrit was associated with recurrence risk only among women. After five years, the probability of recurrence was 9.9% (95% CI 3.7%-15.7%), 15.6% (95% CI 9.7%-21.2%) and 25.5% (95% CI 15.1%-34.6%) in women, and was 29.2% (95% CI 21.1%-36.5%), 30.1% (95% CI 24.1%-35.7%) and 30.8% (95% CI 22.0%-38.7%) in men for hematocrits in the first, second and third tertile, respectively. Men had a higher recurrence risk (1.9; 95% CI 1.1-2.7; p = 0.03), which dropped by 23.5% after adjustment for hematocrit. Hematocrit was not a significant mediator of the sex-difference in recurrence risk (p = 0.223).<h4>Conclusions</h4>High hematocrit is associated with the recurrence only in women. The different recurrence risk between men and women is possibly partly explained by hematocrit.
format	article
author	Lisbeth Eischer Verena Tscholl Georg Heinze Ludwig Traby Paul A Kyrle Sabine Eichinger
author_facet	Lisbeth Eischer Verena Tscholl Georg Heinze Ludwig Traby Paul A Kyrle Sabine Eichinger
author_sort	Lisbeth Eischer
title	Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
title_short	Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
title_full	Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
title_fullStr	Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
title_full_unstemmed	Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
title_sort	hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/3939f7a1fad14d4291dae1952ed21202
work_keys_str_mv	AT lisbetheischer hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy AT verenatscholl hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy AT georgheinze hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy AT ludwigtraby hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy AT paulakyrle hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy AT sabineeichinger hematocritandtheriskofrecurrentvenousthrombosisaprospectivecohortstudy
_version_	1718423657444802560

Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.

Ejemplares similares